L P Garrison

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. doi request reprint Performance-Based Risk-Sharing Arrangements-Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA Electronic address
    Value Health 16:703-19. 2013
  2. pmc The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
    Louis P Garrison
    University of Washington School of Pharmacy, Box 357630, Seattle, Washington 98195, USA
    Oncologist 18:27-36. 2013
  3. pmc A review of data needed to parameterize a dynamic model of measles in developing countries
    Emily K Szusz
    Department of Mathematics and Statistics, University of Guelph, Guelph, Canada
    BMC Res Notes 3:75. 2010
  4. pmc Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    BMC Health Serv Res 9:192. 2009
  5. doi request reprint A flexible approach to evidentiary standards for comparative effectiveness research
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Health Aff (Millwood) 29:1812-7. 2010
  6. doi request reprint Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Pharmacoeconomics 28:855-65. 2010
  7. doi request reprint Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II
    Louis P Garrison
    University of Washington, Seattle, WA 98195 7630, USA
    Value Health 13:8-13. 2010
  8. doi request reprint The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Health Sciences Building, Seattle, WA 98195 7630, USA
    Value Health 12:1118-23. 2009
  9. doi request reprint Will pharmacogenomics disrupt the U.S. health care system? No
    L P Garrison
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Public Health Genomics 12:185-90. 2009
  10. ncbi request reprint Linking pharmacogenetics-based diagnostics and drugs for personalized medicine
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Health Aff (Millwood) 25:1281-90. 2006

Detail Information

Publications27

  1. doi request reprint Performance-Based Risk-Sharing Arrangements-Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA Electronic address
    Value Health 16:703-19. 2013
    ..As an innovation in and of themselves, PBRSAs should also be evaluated from a long-run societal perspective in terms of their impact on dynamic efficiency (eliciting the optimal amount of innovation). ..
  2. pmc The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
    Louis P Garrison
    University of Washington School of Pharmacy, Box 357630, Seattle, Washington 98195, USA
    Oncologist 18:27-36. 2013
    ..We conclude that VMP is highly likely to be cost-effective compared with MP, MPT, and MPR-R...
  3. pmc A review of data needed to parameterize a dynamic model of measles in developing countries
    Emily K Szusz
    Department of Mathematics and Statistics, University of Guelph, Guelph, Canada
    BMC Res Notes 3:75. 2010
    ..Our objective was to review the literature on measles epidemiology in low-income countries, with a particular focus on data that are needed to parameterize dynamic models...
  4. pmc Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    BMC Health Serv Res 9:192. 2009
    ..We estimated the potential impact of task-shifting on costs of antiretroviral therapy (ART) and physician supply in Uganda. The study was performed at the Infectious Diseases Institute (IDI) clinic, a large urban HIV clinic...
  5. doi request reprint A flexible approach to evidentiary standards for comparative effectiveness research
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Health Aff (Millwood) 29:1812-7. 2010
    ..We argue that the public interest will best be served if the institute develops a balanced and flexible approach to deciding which types of studies to fund...
  6. doi request reprint Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Pharmacoeconomics 28:855-65. 2010
    ..All said, it would seem that BRA and CER should be neither strangers nor strange bedfellows, but may need to be coaxed into being bedfellows...
  7. doi request reprint Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II
    Louis P Garrison
    University of Washington, Seattle, WA 98195 7630, USA
    Value Health 13:8-13. 2010
    ....
  8. doi request reprint The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Health Sciences Building, Seattle, WA 98195 7630, USA
    Value Health 12:1118-23. 2009
    ....
  9. doi request reprint Will pharmacogenomics disrupt the U.S. health care system? No
    L P Garrison
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Public Health Genomics 12:185-90. 2009
    ..Nonetheless, the sustainability of the projected growth in health spending is in question. Profound reforms are likely, but improved knowledge of our human biology will more likely be a constructive factor as we adapt to these changes...
  10. ncbi request reprint Linking pharmacogenetics-based diagnostics and drugs for personalized medicine
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Health Aff (Millwood) 25:1281-90. 2006
    ..Both strong intellectual property and value-based, flexible pricing systems will be important in making personalized medicine a reality...
  11. ncbi request reprint Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Health Aff (Millwood) 26:684-95. 2007
    ....
  12. ncbi request reprint Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Cancer 110:489-98. 2007
    ..A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials...
  13. ncbi request reprint Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report
    Louis P Garrison
    University of Washington, Seattle, WA 98195, USA
    Value Health 10:326-35. 2007
    ....
  14. ncbi request reprint A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Drug Metab Rev 40:377-401. 2008
    ..How well the numerous important stakeholders - both private and public - address these issues will be critical for pharmacogenomics to deliver on its promise...
  15. doi request reprint Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis
    Josh John Carlson
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Cancer Res Clin Oncol 135:1483-93. 2009
    ....
  16. doi request reprint The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
    ..The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC)...
  17. pmc A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice
    David L Veenstra
    Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 12:686-93. 2010
    ..To address these issues, this study presents a risk-benefit framework for assessing the health-related utility of genomic tests...
  18. doi request reprint Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
    ..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
  19. ncbi request reprint Implications of Part D for mentally ill dual eligibles: a challenge for Medicare
    Nancy E Morden
    Department of Family Medicine, University of Washington School of Medicine, Seattle, USA
    Health Aff (Millwood) 25:491-500. 2006
    ..We discuss the details and policy implications of this challenge...
  20. doi request reprint Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer
    Jennie H Best
    Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA
    Expert Rev Pharmacoecon Outcomes Res 10:103-14. 2010
    ..e., providing good value for money) but, furthermore, would actually be cost saving in the majority of country settings...
  21. doi request reprint Preference values associated with stage III colon cancer and adjuvant chemotherapy
    Jennie H Best
    University of Washington, Seattle, WA, USA
    Qual Life Res 19:391-400. 2010
    ..To elicit preference values for health states associated with Stage III colon cancer (CRC) and to explore the effect of neuropathy associated with current adjuvant treatment...
  22. ncbi request reprint Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests
    Scott D Ramsey
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Am J Manag Care 12:197-202. 2006
    ....
  23. doi request reprint The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review
    J H Best
    Medical Research and Development, Amylin Pharmaceuticals, Inc, San Diego, CA, USA
    Diabetes Obes Metab 14:387-98. 2012
    ..Improvements in A1C, FG, weight and SBP in the observational studies in this review were consistent with improvements observed in controlled clinical trials...
  24. doi request reprint Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007
    J T Cross
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington, USA
    Clin Pharmacol Ther 89:429-36. 2011
    ..We adapted a mathematical diabetes model to estimate NB and uncertainty of diabetes monotherapy...
  25. ncbi request reprint The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable
    Louis P Garrison
    Value Health 6:6-8. 2003
  26. ncbi request reprint Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK
    Beate Sander
    Division of Clinical Decision Making and Health Care Research, University Health Network, Toronto, Ontario, Canada
    Pharmacoeconomics 24:373-86. 2006
    ..To assess the cost effectiveness and cost utility of preventing post-exposure influenza infection using the neuraminidase inhibitor oseltamivir from a healthcare payer's perspective in the UK...
  27. doi request reprint Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research
    Steven K Takemoto
    National Institute of Transplantation, S Mark Taper Foundation Transplant Center, Los Angeles, CA 90057, USA
    Transplantation 86:18-25. 2008
    ..A case is made for regulatory and reimbursement authorities to use outcomes research when making efficacy, effectiveness, and coverage decisions in transplantation...